重新构想心脏病发病率和死亡率会议:通往系统水平改善的道路
Victor Redmon1, David Lewandowski1, Nunzio Gaglianello1
1Division of Cardiology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
JACC. Case reports
|November 14, 2025
概括
重新设计的发病率和死亡率 (M&M) 会议通过将重点从问责制转移到系统改进来促进心理安全和学习. 这种协作方法提高了参与度,并推动了优质的患者护理计划.
科学领域:
- 心脏病学 心脏病学
- 医学教育 医学教育
- 提高质量 提高质量
背景情况:
- 传统的发病率和死亡率 (M&M) 会议可以创造一个惩罚性的氛围,因为强调错误识别和问责制.
- 这种环境可能会抑制公开讨论,并阻碍学习机会.
研究的目的:
- 在心脏病学M&M会议中促进心理安全和增强学习.
- 将M&M会议从以错误为中心的模式转变为系统级改进的协作论坛.
主要方法:
- 在威斯康星州医学院进行了需求评估.
- M&M会议格式被重新设计,包括结构化的案例介绍,匿名反和以患者为中心的观点.
- 实施了季度M&M董事会审查,以确定主题,追踪问题和后续行动.
主要成果:
- 重新设计的M&M格式成功地促进了心理安全和有意义的参与.
- 结构化的后续机制提高了连续性,并促进了系统级改进.
- 修订后的M&M方法赋予实习生领导质量改进计划的权力.
结论:
- 重新设计的M&M会议增强了心理安全和参与度.
- 系统层面的改进是由结构化的后续机制驱动的.
- M&M会议对于识别改进机会和促进质量改进和患者安全方面的领导力至关重要.
更多相关视频
相关概念视频
Cardiomyopathy V: Interprofessional Care
323
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
323
Cardiomyopathy III: Hypertrophic Cardiomyopathy
380
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
380
Coronary Artery Disease V: Interprofessional Care
207
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
207
Cardiomyopathy II: Dilated Cardiomyopathy
451
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
451
Acute Coronary Syndrome IV: Interprofessional Care
205
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
205
Cardiomyopathy I: Introduction and Classification
488
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
488


